



EUROPEAN COMMISSION  
DIRECTORATE-GENERAL RESEARCH & INNOVATION  
Directorate E - Health  
RTD-E

Brussels

Andre BOONSTRA  
ERASMUS UNIVERSITEIT MEDISCH  
CENTRUM ROTTERDAM  
S GRAVENDIJKWAL 230  
3015 CE ROTTERDAM  
NETHERLANDS

Subject: Horizon 2020 Framework Programme  
Call for proposals: H2020-SC1-BHC-2018-2020 (H2020-SC1-2018-Single-Stage-RTD)  
Proposal: 825510 — ESCALON  
Evaluation result letter — GAP invitation letter

Dear Madam Sir,

I am writing in connection with your proposal for the above-mentioned call.

Having completed the evaluation, we are pleased to inform you that your proposal has passed this phase and that the Commission would now like to start grant preparation.

Please find enclosed the evaluation summary report (ESR), based on the comments and opinion of the experts that evaluated the proposal for the Commission.

**Invitation to grant preparation**

Grant preparation will be based on the following:

1. **Proposal:** 825510 — ESCALON
2. **Topic:** SC1-BHC-18-2018 — Translational collaborative cancer research between Europe and the Community of Latin American and Caribbean States (CELAC)
3. **Type of action:** Research and Innovation action
4. **Project officer:** Ioannis VOULDIS

Non-communicable diseases and the challenge of healthy ageing

⚠ Please always use the Participant Portal messaging function (via your [Participant Portal account](#)). Do NOT contact the project officer via other means (e-mail, letter, etc) — unless explicitly asked to do so.

5. Maximum grant amount:

Requested EU contribution (according to proposal):

Maximum grant amount (proposed amount, after ev

6. Duration of the action: 48 months

7. Action & budget:

The description of the action (DoA) (Annex 1 to the grant agreement) and the estimated budget for the action (Annex 2 to the grant agreement) must be based on the proposal submitted.

⚠ Please be aware that you may have to change your 'description of the action', in order to address ethics and security issues.

⚠ Please note that you may normally NOT make changes to the project/project budget/ consortium composition (including linked third parties). Please immediately inform the project officer (see above), if you need to make a change (e.g. because one of the consortium members went bankrupt and can no longer participate).

8. Timetable & deadlines for grant preparation

9. Fully electronic grant preparation via the Participant Portal

Please use your [Participant Portal account](#) to prepare your grant (including signature of the agreement). Do NOT contact the Commission via other means (e-mail, letter, etc) — unless explicitly asked to do so.

Please be aware that all linked third parties (that are part of your proposal) must be registered and validated as legal entities in the Participant Portal [Beneficiary Register](#).

⚠ Register them immediately, if not already done.


Please note that some of your legal and financial data in the Beneficiary Register is 'read-only' and can be updated only by your LEAR (via your Participant Portal account on the My Organisation(s) page). During grant preparation, you will therefore be asked to appoint a LEAR.

Please note that the data (from your proposal, the Beneficiary Register or grant preparation) may be used by the Commission for monitoring and statistical purposes.

**10. Other information**

In addition, please note that you are very welcome to attend the Horizon 2020 Coordinators' Day, organized on 21st September 2018 in Brussels. The event will provide all details on the preparation and signature of your grant agreement. Agenda and registration are available under the following link: <https://ec.europa.eu/digital-single-market/events/cf/coordinators-day-on-grant-agreement-preparation-21092018/register.cfm>. We also encourage you to contact your Project Officer and Legal Officer and to schedule an individual meeting with them in order to discuss your project specifically. Preferable date for individual meetings is Thursday, 20th September (the day before Coordinators' Day), however if not possible due to your travel schedule, you can also discuss other options with the EC Officers.

① For more information on grant preparation, see the [Online Manual](#) on the Participant Portal.



Yours faithfully,

Irene NORSTEDT  
Acting Director

Enclosures: Evaluation summary report (ESR)



## LETTER OF AGREEMENT

Following are the terms and conditions applying to grants made by the Robert Wood Johnson Foundation (referred to as "the Foundation," "we," or "us"). As a grantee (referred to as "grantee" or "you"), you should read this carefully; your signature on this form constitutes your acceptance of all the terms and conditions. As used in this form, the term "grant" includes any income you derive from the grant.

Awardee: Regents of the University of Minnesota  
I.D.: [REDACTED]  
Amount: [REDACTED]  
Purpose: Hepatocyte gene expression during hepatitis C infection and treatment -- Jose D. Debes, MD, MS  
Project Information: Grant Period: July 1, 2017 through June 30, 2021  
Project Director: Jose D. Debes, MD, MS, 612-624-9996  
(debes003@umn.edu)

**1. PURPOSE AND ADMINISTRATION.** You will directly administer the project or program being supported by the grant and agree that no grant funds shall be used in any way other than as specifically set forth in this Letter of Agreement and the final proposal, budget and related documents, all as approved by the Foundation (the "Approved Grant Documents") without the Foundation's prior written consent. You further agree that no grant funds shall be disbursed to any organization or entity, whether or not formed by you, except as specifically set forth in the Approved Grant Documents.

Infection with hepatitis C virus (HCV) leads to cirrhosis and hepatocellular carcinoma. The molecular pathways leading to both complications are largely unknown. Liver aspiration will be performed in patients with HCV before and after antiviral treatment to assess changes in human gene expression. These studies will elucidate how HCV manipulates the expression of human genes to establish and maintain chronic infection, leading to cirrhosis and hepatocellular carcinoma.

No changes may be made to the nature or scope of the program or project being supported by this grant without the express written consent of the Foundation.

## 2. USE OF GRANT FUNDS.

A. No part of the grant shall be used to carry on propaganda or otherwise attempt to influence legislation within the meaning of Section 4945(d)(1) of the Internal Revenue Code.

B. No part of the grant shall be used to attempt to influence the outcome of any specific public election or to carry on, directly or indirectly, any voter registration drive within the meaning of Section 4945(d)(2) of the Internal Revenue Code.



## CERTIFICADO PARTICIPACIÓN

12 de abril de 2021

Alejandra Vidales Carmona, Directora del Programa Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT) de la Agencia Nacional de Investigación y Desarrollo, certifica que Don/ña MARCO ANTONIO ARRESE JIMENEZ, 9034107-3, ha participado como investigador/a en los proyectos que a continuación se detallan:

Proyecto	Título	Tipo de Participación
1990519	SECRECIÓN BILIAR Y EMBARZO: ESTUDIO DE LA EXPRESIÓN DE PROTEÍNAS TRANSPORTADORAS DE ÁCIDOS BILIARES Y ANIONES ORGÁNICOS EN LA CIRCULACIÓN ENTEROHEPÁTICA DURANTE LA PRENEZ.	RESPONSABLE
1020641	INJURIA HEPATOCELULAR EN LA ESTEATOSIS HEPÁTICA: ESTUDIO DE LA SUSCEPTIBILIDAD AL DAÑO HEPÁTICO EXPERIMENTAL EN ANIMALES GENÉTICAMENTE OBESOS.	RESPONSABLE
1191145	ASSESSING THE ROLE OF BILE ACIDS (BA) IN NASH-RELATED HEPATOCELLULAR CARCINOMA	RESPONSABLE
1150327	LIVER INJURY IN NON-ALCOHOLIC FATTY LIVER DISEASE: EXPLORING NEW MODULATORS AND BIOMARKERS	RESPONSABLE
1110455	EXPLORING NEW PATHOPHYSIOLOGICAL PATHWAYS IN NONALCOHOLIC FATTY LIVER DISEASE	RESPONSABLE
1080170	HIGADO GRASO NO ALCOHOLICO: ESTUDIOS CLÍNICOS Y EXPERIMENTALES SOBRE EL ROL DE LOS ÁCIDOS BILIARES, LAS ADIPOQUINAS Y EL ESTRÉS DEL RETÍCULO ENDOPLASMÁTICO	RESPONSABLE
1050780	FACTORES DETERMINANTES Y ESTRATEGIAS DE MODULACIÓN DE LA INJURIA HEPÁTICA EXPERIMENTAL.	RESPONSABLE
1940569	ERRADICACIÓN DE HELICOBACTER PYLORI EN UN MEDIO DE ALTA PREVALENCIA FACTIBILIDAD Y TASAS DE REINFECCIÓN O RECIDIVA EN PACIENTES CON ÚLCERA DUODENAL.	COINVESTIGADOR
1000563	MECANISMOS DE LA COLESTASIA POR ISQUEMIA Y REPERFUSIÓN DEL HIGADO: ESTUDIO DE LA EXPRESIÓN DE PROTEÍNAS TRANSPORTADORAS Y ENZIMAS DE LA MEMBRANA PLASMÁTICA, Y DEL TRANSPORTE TRANSCITÓTICO HEPATOCELULAR.	COINVESTIGADOR
1212066	CARDIOVASCULAR AND NONALCOHOLIC FATTY LIVER DISEASES AMONG GALLSTONE AND CHOLECYSTECTOMY PATIENTS AND IMPACT OF A NOVEL DIET AND MUSCLE TRAINING PROGRAM	COINVESTIGADOR
1211879	DECIPHERING MUSCLE-LIVER CONNECTIONS IN MAFLD: EXPERIMENTAL AND CLINICAL STUDIES	COINVESTIGADOR



1200227	BILE ACIDS AND EXTRACELLULAR VESICLES AS NOVEL BIOMARKERS TO STRATIFY THE SEVERITY OF ALCOHOL-RELATED LIVER DISEASE: FROM BINGE DRINKING TO ALCOHOLIC HEPATITIS	COINVESTIGADOR
1191183	DISSECTING THERAPEUTIC ROLE OF GROWTH HORMONE AND INSULIN-LIKE GROWTH FACTOR 1 IN CHRONIC LIVER DISEASE: BALANCING BETWEEN HEPATOCYTE PROTECTION AND ONCOGENIC POTENTIAL	COINVESTIGADOR
1190419	NOVEL RADIOLOGIC AND METABOLOMIC PROFILING OF ADRENAL TUMORS TO IDENTIFY CARDIOMETABOLIC RISK	COINVESTIGADOR
1170395	CHOLECYSTECTOMY AND NON-ALCOHOLIC FATTY-LIVER DISEASE: TESTING CAUSALITY IN A CHILEAN PROSPECTIVE COHORT OF CHRONIC DISEASES.	COINVESTIGADOR
1150311	EVALUATING SOMATOTROPIC AXIS DYSREGULATION AND PROTECTIVE ROLE OF GROWTH HORMONE AND INSULIN LIKE GROWTH FACTOR 1 SUPPLEMENTATION IN NON ALCOHOLIC FATTY LIVER DISEASE	COINVESTIGADOR
1150186	SEARCHING FOR COMMON PATHOGENIC PATHWAYS LEADING TO NEURONAL AND HEPATIC DAMAGE IN NIEMANN-PICK DISEASES.	COINVESTIGADOR
1130146	EFFECT OF CHOLECYSTECTOMY ON SERUM TRIGLYCERIDE AND HEPATIC FAT LEVELS IN WOMEN AND THE DEVELOPMENT OF NONALCOHOLIC FATTY LIVER DISEASE IN MICE.	COINVESTIGADOR
1120877	ELUCIDATING THE MECHANISMS OF GLYCEMIC CONTROL AFTER METABOLIC SURGERY	COINVESTIGADOR
1110310	RELEVANCE OF OXIDATIVE DAMAGE DUE TO MITOCHONDRIAL DYSFUNCTION AND/OR DECREASED ANTIOXIDANT DEFENSES IN THE PATHOGENESIS OF NIEMANN PICK TYPE C DISEASE	COINVESTIGADOR
1100020	ROLE OF THE GALLBLADDER IN THE REGULATION OF HEPATIC TRIGLYCERIDE METABOLISM: IMPLICATIONS FOR THE PATHOGENESIS OF NON-ALCOHOLIC FATTY LIVER DISEASE.	COINVESTIGADOR
3140396	Hitting the brakes in the innate immune response: synergic action of TGR5 and andrographolide in non-alcoholic steatohepatitis	PATROC.POSTDOC

Se extiende el presente certificado a petición del/de la interesado/a, para los fines que estime conveniente.



Alejandra Vidales Carmona  
Directora Programa FONDECYT  
Fondo Nacional de Desarrollo Científico y Tecnológico



Código de verificación: 4471fbf6-8f6d-4cde-97c2-f302e686491e

Folio: CEL00026648

Este certificado cuenta con Firma Electrónica Avanzada, su autenticidad podrá ser verificada en

<https://servicios.conicyt.cl/web/certificados-en-linea/#/portal-validacion/ingreso/CEL00026648/4471fbf6-8f6d-4cde-97c2-f302e686491e>

Este certificado se encuentra vigente por 365 días a partir de su fecha de emisión